FDA Drugs recall ·
glipiZIDE, Extended-Release Tablets, 2.5 mg… recall
- Recall number
- D-0202-2025
- Date
- (initiated December 17, 2024)
- Company / brand
- Amerisource Health Services LLC
2550 John Glenn Ave Ste A, Columbus, OH, United States - Category
- Drugs › Class II
- Classification
- Class II
- Status
- Terminated
- Units affected
- 2,028 units (cartons of 30 individual unit doses)
- Initiated by
- Voluntary: Firm initiated
Read the official FDA notice ↗
Product
glipiZIDE, Extended-Release Tablets, 2.5 mg, 30-count (3x10 blister cards) carton, Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC: 60687-480-21, Unit Dose NDC: 60687-480-11
Why was it recalled?
Failed Dissolution Specifications:
What should you do?
FDA enforcement reports do not list a consumer remedy. Check the product codes below against what you have; if it matches, stop using it and follow the instructions in the firm's or FDA's official notice, or contact the company. If you have health concerns, contact your healthcare provider.
Product codes & lot numbers
Lot # 1012910, Exp Date: 04/30/2025
Distribution
Nationwide in the USA
What does Class II mean?
Class II means use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or the probability of serious harm is remote.
Source: FDA (drugs), recall D-0202-2025. Official notice. Republished from public data; RecallFlag is not affiliated with the FDA.